Core Viewpoint - A class action has been filed against Lantheus Holdings, Inc. for allegedly misleading investors regarding the competitive position of its key product, Pylarify, during a specified period [1][2]. Group 1: Allegations and Misleading Statements - The complaint alleges that Lantheus made materially false and misleading statements about Pylarify's competitive position, failing to accurately assess pricing and competitive dynamics [2][3]. - It is claimed that Lantheus did not properly disclose the implications of a price increase in early 2025, which created opportunities for competitive pricing and risked Pylarify's revenue and growth potential [2]. Group 2: Financial Impact and Stock Performance - On August 6, 2025, Lantheus announced disappointing results, revealing an 8.3% year-over-year decline in Pylarify's performance and significantly reduced growth expectations for fiscal year 2025 [4]. - Following this announcement, Lantheus' stock price dropped from $72.83 per share on August 5, 2025, to $51.87 per share on August 6, 2025, marking a decline of approximately 28.8% in one day [4].

Core Viewpoint - A class action lawsuit has been initiated against PubMatic, Inc. on behalf of investors who suffered losses during the specified Class Period from February 27, 2025, to August 11, 2025 [1][2]. Summary by Relevant Sections - **Lawsuit Details** - The lawsuit aims to recover losses for investors who purchased PubMatic securities during the Class Period [1]. - Investors have until October 20, 2025, to seek appointment as lead plaintiff [2]. - **Allegations Against Defendants** - The lawsuit alleges that the Defendants made materially false and misleading statements and failed to disclose adverse facts about PubMatic's business and operations [3]. - Specific allegations include: - A major Demand-Side Platform (DSP) buyer was shifting clients to a new platform, impacting PubMatic's ad spend and revenue [3]. - Defendants' positive statements regarding the company's prospects were misleading and lacked a reasonable basis due to the undisclosed issues [3].

Core Viewpoint - Kessler Topaz Meltzer & Check, LLP is investigating potential violations of federal securities laws on behalf of Fortinet investors following disappointing Q2 2025 financial results, which led to stock downgrades by analysts due to concerns over the company's firewall refresh cycle [1][2]. Group 1 - Fortinet reported disappointing second-quarter 2025 financial results on August 6, 2025 [1]. - Following the financial report, Fortinet's stock price fell by $21.28 per share, or 22.03%, closing at $75.30 per share on August 7, 2025 [2]. - Analysts downgraded their ratings on Fortinet's stock due to concerns regarding the company's firewall refresh cycle [1]. Group 2 - Kessler Topaz Meltzer & Check, LLP has a history of prosecuting class actions involving securities fraud and breaches of fiduciary duties, recovering billions for investors [2]. - The firm represents investors, consumers, and whistleblowers, contributing to corporate governance reform [2]. - For further information, Kessler Topaz Meltzer & Check, LLP provides contact details for inquiries regarding the investigation [3].

Core Viewpoint - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Simulations Plus, Inc. regarding possible violations of federal securities laws, particularly related to alleged misrepresentations and omissions by the company and its executives [1] Company Background - Simulations Plus is a software company that serves the pharmaceutical, biotechnology, and chemical industries [3] - In June 2024, the company acquired Pro-ficiency Holdings, Inc., claiming this acquisition would double its total addressable market and serve as a key driver of growth [3] Recent Developments - On June 11, 2025, Simulations Plus announced disappointing preliminary results for Q3 2025, attributing the downturn to "market uncertainties," which led to a stock price drop of over 24%, from $26.44 to $20.05 per share [4] - Following this, on July 14, 2025, the company reported a $77.2 million charge related to prior acquisitions and dismissed its auditor, Grant Thornton LLP, which raised concerns about unresolved issues with segment reporting and internal controls [4] - The dismissal of the auditor and the acknowledgment of unresolved issues caused the stock to fall nearly 26%, from $17.47 to $12.97 per share [4]

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Unicycive Therapeutics, Inc. securities, alleging misleading statements regarding the company's compliance with FDA manufacturing requirements and the regulatory prospects of its New Drug Application [1][5]. Group 1: Lawsuit Details - The class action lawsuit is filed for securities purchased between March 29, 2024, and June 27, 2025 [1]. - Investors who purchased Unicycive securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - The lawsuit claims that Unicycive's readiness to meet FDA manufacturing compliance was overstated, along with the regulatory prospects of its oxylanthanum carbunate New Drug Application [5]. Group 2: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must file a motion with the court by October 14, 2025, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions for investors [4].

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of America's Car-Mart, Inc. ("Car-Mart†or the "Company†) (NASDAQ: CRMT) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON AMERICA'S CAR-MART, INC. (CRMT), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On July 15, 2025, Car-Mart disclosed it would delay fi. ...

Core Viewpoint - The article discusses a class action lawsuit against Dow Inc. for alleged violations of the Securities Exchange Act of 1934, with claims of misleading statements regarding the company's financial health and ability to manage macroeconomic challenges [1][3]. Group 1: Lawsuit Details - The class action lawsuit is titled Sarti v. Dow Inc., and it involves purchasers of Dow securities from January 30, 2025, to July 23, 2025, with a deadline of October 28, 2025, for lead plaintiff applications [1]. - Allegations include that Dow overstated its ability to handle macroeconomic and tariff-related challenges, and understated the negative impacts on its business, particularly regarding competitive pressures and declining global sales [3]. Group 2: Financial Performance - On June 23, 2025, BMO Capital downgraded Dow's stock from "Market Perform" to "Underperform," reducing the price target from $29.00 to $22.00 due to ongoing weakness in key markets [4]. - Dow reported a non-GAAP loss per share of $0.42 for Q2 2025, significantly worse than the expected loss of approximately $0.17 to $0.18, with net sales of $10.1 billion, a 7.3% year-over-year decline [5]. - Following the disappointing earnings report, Dow announced a dividend cut from $0.70 to $0.35 per share, citing the need for financial flexibility in a challenging macroeconomic environment, which led to a stock price drop of over 17% [5]. Group 3: Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Dow securities during the class period to seek lead plaintiff status, representing the interests of the class [6]. Group 4: Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [7]. - The firm has been recognized for securing significant monetary relief for investors, including the largest recovery in history of $7.2 billion in the Enron case [8].

Core Viewpoint - Capricor Therapeutics, Inc. is facing a class action lawsuit due to allegations of misleading investors regarding its lead cell therapy candidate, deramiocel, for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD) [1][2]. Summary by Relevant Sections Allegations - The complaint claims that Capricor provided investors with overly positive information about deramiocel's potential to obtain a Biologics License Application (BLA) from the FDA while concealing adverse facts about its safety and efficacy data from the Phase 2 HOPE-2 trial [1]. - On July 11, 2025, Capricor announced it received a Complete Response Letter (CRL) from the FDA, denying the BLA due to insufficient evidence of effectiveness and the need for additional clinical data [1]. Stock Price Impact - Following the announcement of the CRL, Capricor's stock price dropped from $11.40 per share on July 10, 2025, to $7.64 per share on July 11, 2025, reflecting a significant decline in investor confidence [1]. Class Action Details - Shareholders who purchased shares during the class period from October 9, 2024, to July 10, 2025, are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for September 15, 2025 [2]. - Participants will be enrolled in a portfolio monitoring system to receive updates on the case [2]. Law Firm's Mission - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices, seeking recovery for losses incurred due to misleading statements or omissions by companies [3].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Quanex Building Products Corporation and its officers or directors, following disappointing financial results that led to a significant drop in stock price [1][3]. Financial Performance - On September 4, 2025, Quanex reported non-GAAP earnings per share of $0.69 for Q3 2025, which was $0.15 below consensus estimates [3]. - The company's stock price fell by $2.73, or 13.06%, closing at $18.18 per share on September 5, 2025, in response to the earnings miss [3]. Challenges Faced - The CEO of Quanex highlighted several challenges, including the need to re-segment the business, macroeconomic uncertainty, low consumer confidence, and operational issues related to the legacy Tyman window and door hardware business in Mexico [3].

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud and unlawful business practices involving Fly-E Group, Inc. following a damaging report that led to a significant decline in the company's stock price [1][3]. Group 1: Investigation Details - Pomerantz LLP is representing investors of Fly-E Group, Inc. and is looking into whether the company and its officers or directors have engaged in securities fraud [1]. - The investigation was prompted by a report from The Bear Cave, which accused Fly-E of stock manipulation and being involved in a pump-and-dump scheme [3]. Group 2: Stock Performance - Following the publication of The Bear Cave report, Fly-E's stock price experienced a sharp decline over several consecutive trading sessions [3]. Group 3: Company Background - Fly-E Group, Inc. is under scrutiny for producing products that The Bear Cave claims endanger public safety in New York [3]. - Pomerantz LLP has a long history in corporate and securities class litigation, having recovered numerous multimillion-dollar damages awards for victims of securities fraud [4].